Ligand Pharmaceuticals Incorporated
LGND
Pozycja w akcjach
#3114
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Cena akcji
$291.18
Ostatnia synchronizacja: 2026-07-31
Kapitalizacja rynkowa
$5.84B
Zmiana (1 dzień)
-1.73%
Zmiana (1 rok)
55.99%
Kraj
US
Handel Ligand Pharmaceuticals Incorporated (LGND)
Kategoria
Healthcare
Wskaźnik P/E dla Ligand Pharmaceuticals Incorporated (LGND)
Wskaźnik P/E na dzień October 2026 TTM: 29.47
Według najnowszych raportów finansowych i ceny akcji Ligand Pharmaceuticals Incorporated, obecny wskaźnik P/E (TTM) wynosi 29.47. Na koniec 2023 wskaźnik P/E wynosił 23.69.
Historia wskaźnika P/E dla Ligand Pharmaceuticals Incorporated od 2000 do 2026
Wskaźnik P/E na koniec każdego roku
| Rok | Wskaźnik P/E | Zmień |
|---|---|---|
| 2026 (TTM) | 29.47 | -106.06% |
| 2024 | -486.05 | -2,151.90% |
| 2023 | 23.69 | -170.13% |
| 2022 | -33.78 | -175.13% |
| 2021 | 44.96 | -108.34% |
| 2020 | -539.23 | -17,229.80% |
| 2019 | 3.15 | -86.17% |
| 2018 | 22.77 | -90.07% |
| 2017 | 229.37 | -117.73% |
| 2016 | -1.29K | -15,615.10% |
| 2015 | 8.34 | -90.77% |
| 2014 | 90.36 | -3.41% |
| 2013 | 93.55 | -112.45% |
| 2012 | -751.68 | -3,378.49% |
| 2011 | 22.93 | -264.01% |
| 2010 | -13.98 | -88.91% |
| 2009 | -126.08 | 4,626.87% |
| 2008 | -2.67 | -258.53% |
| 2007 | 1.68 | -106.05% |
| 2006 | -27.81 | 96.61% |
| 2005 | -14.14 | -25.56% |
| 2004 | -19.00 | -31.44% |
| 2003 | -27.72 | 290.20% |
| 2002 | -7.10 | -53.97% |
| 2001 | -15.43 | 129.72% |
| 2000 | -6.72 | 0.00% |
Wskaźnik P/E dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/E | Różnica wskaźnika P/E | Kraj |
|---|---|---|---|
| 28.78 | -2.33% |
US
|
|
| -28.36 | -196.23% |
US
|
|
| -24.57 | -183.36% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 2.92% |
NL
|
Jak odczytywać wskaźnik P/E?
Wskaźnik Cena/Zysk (P/E) mierzy relację między ceną akcji firmy a jej zyskiem na akcję.
Niski, ale dodatni P/E oznacza firmę osiągającą wysokie zyski względem obecnej wyceny i może być niedowartościowana. Wysoki ujemny (bliski 0) P/E wskazuje na duże straty.
Firmy z P/E powyżej 30 lub ujemnym uznaje się zazwyczaj za "akcje wzrostowe", czyli inwestorzy oczekują wzrostu lub przyszłych zysków.
Firmy z dodatnim P/E poniżej 10 uznaje się za "akcje wartościowe", co oznacza, że są już bardzo dochodowe, ale bez dużego potencjału wzrostu.